Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Fenaux P, et al. Among authors: salvi f. N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892. N Engl J Med. 2020. PMID: 31914241 Free article. Clinical Trial.
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Angelucci E, et al. Among authors: salvi f. Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10. Eur J Haematol. 2014. PMID: 24580147 Clinical Trial.
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R. Oliva EN, et al. Among authors: salvi f. Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3. Lancet Haematol. 2017. PMID: 28162984 Clinical Trial.
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
Balleari E, Filiberti RA, Salvetti C, Allione B, Angelucci E, Bruzzone M, Calzamiglia T, Cavaliere M, Cavalleri M, Cilloni D, Clavio M, Crisà E, Da Col A, Danise P, Pilo F, Ferrero D, Finelli C, Gioia D, Lemoli RM, Masiera E, Messa E, Miglino M, Musto P, Natalie Oliva E, Poloni A, Salvi F, Sanna A, Scudeletti M, Tassara R, Santini V. Balleari E, et al. Among authors: salvi f. Cancer Med. 2019 Dec;8(18):7567-7576. doi: 10.1002/cam4.2638. Epub 2019 Oct 27. Cancer Med. 2019. PMID: 31657156 Free PMC article.
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.
Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry. Gyan E, et al. Among authors: salvi f. Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. Br J Haematol. 2016. PMID: 26773632 Free article. No abstract available.
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S. Voso MT, et al. Among authors: salvi f. Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154. Ann Oncol. 2017. PMID: 28368509 Free article. Clinical Trial.
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E. Efficace F, et al. Among authors: salvi f. BMJ Support Palliat Care. 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9. BMJ Support Palliat Care. 2016. PMID: 25204541
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.
Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V. Messa E, et al. Among authors: salvi f. Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076178 Free PMC article. Clinical Trial. No abstract available.
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).
Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT. Fabiani E, et al. Among authors: salvi f. Br J Haematol. 2019 Jun;185(5):954-957. doi: 10.1111/bjh.15655. Epub 2018 Nov 8. Br J Haematol. 2019. PMID: 30407614 Free article. No abstract available.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F. Buckstein R, et al. Among authors: salvi f. Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29. Am J Hematol. 2017. PMID: 28675513 Free article.
409 results